Product Code: ONCOGENE_PANEL-25
From £630.00
Registration closed: 28/02/2025
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.
Any molecular test, NGS, Whole exome sequencing
Not applicable
FFPE (artificial materials)
Yes
The Oncogene Panel EQA scheme is designed to tests a laboratory’s ability to detect a range of clinically significant variants in the context of precision medicine for cancer e.g. activating/driver mutations and resistance mutations.
Three mock clinical cases with matching artificial paraffin embedded (FFPE) reference materials (designed to simulate real patient samples). Two 15um thick FFPE sections per case are provided.
NOTE: Samples provided as cut sections (rolled scrolls / curls) only – we cannot provide slide mounted materials.
Variant allele frequencies of the artificial FFPE reference materials have been validated using ddPCR.
Participants will receive an individual report including educational advice and a scheme report which includes additional information from the cohort of participants including geographical spread, methodologies employed, common errors, learning points and scheme statistics allowing participants to benchmark their results.
Each laboratory will also receive a single certificate listing all EQAs participated in with performance result for each year.
No restrictions on number of participants.
Open to laboratories from ALL countries (note: some restrictions may apply*)
*Sanctions, delivery network exceptions, restrictions on importation etc.
added wishlist!
View Wishlist
View Wishlist
Express your interest in ''.